tbuckley/cabot-search huggingface dataset:
Association of Patient Treatment Preference With Dropout and Clinical Outcomes in Adult Psychosocial Mental Health Interventions
Authors: Emma Windle, Helena Tee, Alina Sabitova, Nikolina Jovanovic, Stefan Priebe, Catherine Carr
Journal: JAMA Psychiatry (2019)

<h3>Importance</h3> Receiving a preferred treatment has previously been associated with lower dropout rates and better clinical outcomes, but this scenario has not been investigated specifically for psychosocial interventions for patients with a mental health diagnosis. <h3>Objective</h3> To assess the association of patient treatment preference with dropout and clinical outcomes in adult psychosocial mental health interventions via a systematic review and meta-analysis. <h3>Data Sources</h3> The Cochrane Library, Embase, PubMed, PsychINFO, Scopus, Web of Science, Nice HDAS (Healthcare Databases Advanced Search), Google Scholar, BASE (Bielefeld Academic Search Engine), Semantic Scholar, and OpenGrey were searched from inception to July 20, 2018, and updated on June 10, 2019. <h3>Study Selection</h3> Studies were eligible if they (1) were a randomized clinical trial; (2) involved participants older than 18 years; (3) involved participants with mental health diagnoses; (4) reported data from a group of participants who received their preferred treatment and a group who received their nonpreferred treatment or who were not given a choice; and (5) offered at least 1 psychosocial intervention. <h3>Data Extraction and Synthesis</h3> Two researchers extracted study data for attendance, dropout, and clinical outcomes independently. Both assessed the risk of bias according to the Cochrane tool. Data were pooled using random-effects meta-analyses. <h3>Main Outcomes and Measures</h3> The following 7 outcomes were examined: attendance, dropout, therapeutic alliance, depression and anxiety outcomes, global outcomes, treatment satisfaction, and remission. <h3>Results</h3> A total of 7341 articles were identified, with 34 eligible for inclusion. Twenty-nine articles were included in the meta-analyses comprising 5294 participants. Receiving a preferred psychosocial mental health treatment had a medium positive association with dropout rates (relative risk, 0.62; 0.48-0.80;<i>P</i> &lt; .001;<i>I</i><sup>2</sup> = 44.6%) and therapeutic alliance (Cohen<i>d</i> = 0.48; 0.15-0.82;<i>P</i> = .01;<i>I</i><sup>2</sup> = 20.4%). There was no evidence of a significant association with other outcomes. <h3>Conclusions and Relevance</h3> This is the first review, to our knowledge, examining the association of receiving a preferred psychosocial mental health treatment with both engagement and outcomes for patients with a mental health diagnosis. Patients with mental health diagnoses who received their preferred treatment demonstrated a lower dropout rate from treatment and higher therapeutic alliance scores. These findings underline the need to accommodate patient preference in mental health services to maximize treatment uptake and reduce financial costs of premature dropout and disengagement.
Efficacy and Safety of Dabrafenib in Pediatric Patients with <i>BRAF</i> V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study
Authors: Darren R. Hargrave, Eric Bouffet, Uri Tabori, Alberto Broniscer, Kenneth J. Cohen, Jordan R. Hansford, Birgit Geoerger, Pooja Hingorani, Ira J. Dunkel, Mark W. Russo, Lillian Tseng, Kohinoor Dasgupta, Eduard Gasal, James A. Whitlock, Mark W. Kieran
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Pediatric low-grade glioma (pLGG) is the most prevalent childhood brain tumor. Patients with BRAF V600 mutation–positive pLGG may benefit from treatment with dabrafenib. Part 2 of a phase I/IIa study, open-label study (NCT01677741) explores the activity and safety of dabrafenib treatment in these patients. Patients and Methods: Patients ages 1 to &amp;lt;18 years who had BRAF V600–mutant solid tumors (≥1 evaluable lesion) with recurrent, refractory, or progressive disease after ≥1 standard therapy were treated with oral dabrafenib 3.0 to 5.25 mg/kg/day (part 1) or at the recommended phase II dose (RP2D; part 2). Primary objectives were to determine the RP2D (part 1, results presented in a companion paper) and assess clinical activity (part 2). Here, we report the clinical activity, including objective response rates (ORRs) using Response Assessment in Neuro-Oncology criteria and safety across parts 1 and 2. Results: Overall, 32 patients with pLGG were enrolled (part 1, n = 15; part 2, n = 17). Minimum follow-up was 26.2 months. Among all patients, the ORR was 44% [95% confidence interval (CI), 26–62] by independent review. The 1-year progression-free survival rate was 85% (95% CI, 64–94). Treatment-related adverse events (AE) were reported in 29 patients (91%); the most common was fatigue (34%). Grade 3/4 treatment-related AEs were reported in 9 patients (28%). Conclusions: Dabrafenib demonstrated meaningful clinical activity and acceptable tolerability in patients with BRAF V600–mutant pLGG.
Abstract 12671: Trends in Cardiovascular Mortality and Economic Distress in Communities
Authors: Sameed Ahmed M Khatana, Ashwin Nathan, Elias J Dayoub, Dhruv S Kazi, Robert W Yeh, Peter W Groeneveld, S V Subramanian
Journal: Circulation (2019)

Background: Recent increases in cardiovascular mortality rates for non-elderly US adults have occurred alongside an uneven recovery from the 2007-2008 economic recession and rising income inequalit...
Testing bronchodilator responsiveness
Authors: Martin R. Miller
Journal: European Respiratory Journal (2019)

The recent paper in the European Respiratory Journal by Janson et al . [1] on testing bronchodilator responsiveness suggests that it has no value in distinguishing asthma from COPD. The authors correctly state that “there are many different ways of defining bronchodilator reversibility.” However, they do not then mention any of them other than using the change in forced expiratory volume in 1 s (FEV1) standardised by the start value. This can lead to a sex and size bias in assessing bronchodilator response [2]. One method, that was recommended by the European Respiratory Society many years ago [3], standardises the change in FEV1 by the subject's predicted value and not their start value. Using this method it has been found that a change in FEV1 of 8% of predicted or more due to a bronchodilator was associated with a survival advantage [2]. This approach avoided all the pitfalls around the clinical diagnosis of COPD versus asthma. Previously it has been found that a change in FEV1 of 4% of predicted in COPD patients was associated with subjects being able to appreciate that their breathlessness was improved [4]. A paper in the ERJ suggests that testing bronchodilator responsiveness is not helpful but the authors have not used the most appropriate method <http://bit.ly/2MJR3KM>
Abstract 5729: Use of Strain and Strain Rate Imaging in the Assessment of Regional Left Ventricular Deformation: A Study in Adult Unoperated Patients with Marfan Syndrome
Authors: Anatoli Kiotsekoaglou, George R Sutherland, Bart Bijnens, James C Moggridge, Venedictos Kapetanakis, Michael J Mullen, Dariush K Nassiri, John Camm, Anne H Child
Journal: Circulation (2008)
Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes
Authors: Daniel F. Gudbjartsson, Gudmundur Thorgeirsson, Patrick Sulem, Anna Helgadottir, Arnaldur Gylfason, Jona Saemundsdottir, Eythor Bjornsson, Gudmundur L. Norddahl, Aslaug Jonasdottir, Adalbjorg Jonasdottir, Hannes P. Eggertsson, Solveig Gretarsdottir, Gudmar Thorleifsson, Olafur S. Indridason, Runolfur Palsson, Fridbert Jonasson, Ingileif Jonsdottir, Gudmundur I. Eyjolfsson, Olof Sigurdardottir, Isleifur Olafsson, Ragnar Danielsen, Stefan E. Matthiasson, Snaedis Kristmundsdottir, Bjarni V. Halldorsson, Astradur B. Hreidarsson, Einar M. Valdimarsson, Thorarinn Gudnason, Rafn Benediktsson, Valgerdur Steinthorsdottir, Unnur Thorsteinsdottir, Hilma Holm, Kari Stefansson
Journal: Journal of the American College of Cardiology (2019)

Lipoprotein(a) [Lp(a)] is a causal risk factor for cardiovascular diseases that has no established therapy. The attribute of Lp(a) that affects cardiovascular risk is not established. Low levels of Lp(a) have been associated with type 2 diabetes (T2D). This study investigated whether cardiovascular risk is conferred by Lp(a) molar concentration or apolipoprotein(a) [apo(a)] size, and whether the relationship between Lp(a) and T2D risk is causal. This was a case-control study of 143,087 Icelanders with genetic information, including 17,715 with coronary artery disease (CAD) and 8,734 with T2D. This study used measured and genetically imputed Lp(a) molar concentration, kringle IV type 2 (KIV-2) repeats (which determine apo(a) size), and a splice variant in LPA associated with small apo(a) but low Lp(a) molar concentration to disentangle the relationship between Lp(a) and cardiovascular risk. Loss-of-function homozygotes and other subjects genetically predicted to have low Lp(a) levels were evaluated to assess the relationship between Lp(a) and T2D. Lp(a) molar concentration was associated dose-dependently with CAD risk, peripheral artery disease, aortic valve stenosis, heart failure, and lifespan. Lp(a) molar concentration fully explained the Lp(a) association with CAD, and there was no residual association with apo(a) size. Homozygous carriers of loss-of-function mutations had little or no Lp(a) and increased the risk of T2D. Molar concentration is the attribute of Lp(a) that affects risk of cardiovascular diseases. Low Lp(a) concentration (bottom 10%) increases T2D risk. Pharmacologic reduction of Lp(a) concentration in the 20% of individuals with the greatest concentration down to the population median is predicted to decrease CAD risk without increasing T2D risk.
指南 家族性高胆固醇血症：NICE指南概要
Authors: Anthonv, Wierzbicki, Steve, Humphries, Rubin, Minhas, 张饰, 李玉秀
Journal: BMJ (2008)

为什么阅读本概要？家族性高胆固醇血症在英国的患病率大约是1／500。杂合子家族性高胆固醇血症患者早发冠心病发病风险增高（男性50岁时发病风险〉50％，女性60岁发病风险〉30％），但是情况往往被低估。这篇文章总结了英国国家卫生与临床医疗优选研究所（NICE）关于对家族性高胆固醇血症诊断和治疗的最新指南。
Free Paper Session : HCC ; Therapeutic effect of transcatheter arterial embolization for hypervascular hepatocellular carcinoma: web-based multicenter analysis (초)
Authors: Jun Hyun Baik, Kyung Sup Song, Joon Koo Han, Sung Wook Choo, So Hee Park, Hyun Joo Kong, Sung Wook Shin, Kwang Hun Lee, Jae Kyu Kim
Journal: Clinical and Molecular Hepatology (2011)
DNMT3A with Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks
Authors: Kartika Venugopal, Daniil E Shabashvili, Jianping Li, Luisa M Posada, Richard Lynn Bennett, Yang Feng, Daphne Dupere Richer, Alberto Riva, Santhi Pondugula, Jonathan E. Bird, Jonathan D. Licht, Olga A Guryanova
Journal: Blood (2019)
CTX-712, a Novel Clk Inhibitor Targeting Myeloid Neoplasms with SRSF2 Mutation
Authors: Akinori Yoda, Daisuke Morishita, Akio Mizutani, Yoshihiko Satoh, Yotaro Ochi, Yasuhito Nannya, Hideki Makishima, Hiroshi Miyake, Seishi Ogawa
Journal: Blood (2019)
The human fetal thymus generates invariant effector γδ T cells
Authors: Paola Tieppo, Maria Papadopoulou, Deborah Gatti, Naomi McGovern, Jerry K.Y. Chan, Françoise Gosselin, Glenn Goetgeluk, Karin Weening, Ling Ma, Nicolas Dauby, Alexandra Cogan, Catherine Donner, Florent Ginhoux, Bart Vandekerckhove, David Vermijlen
Journal: The Journal of Experimental Medicine (2019)

In the mouse thymus, invariant γδ T cells are generated at well-defined times during development and acquire effector functions before exiting the thymus. However, whether such thymic programming and age-dependent generation of invariant γδ T cells occur in humans is not known. Here we found that, unlike postnatal γδ thymocytes, human fetal γδ thymocytes were functionally programmed (e.g., IFNγ, granzymes) and expressed low levels of terminal deoxynucleotidyl transferase (TdT). This low level of TdT resulted in a low number of N nucleotide insertions in the complementarity-determining region-3 (CDR3) of their TCR repertoire, allowing the usage of short homology repeats within the germline-encoded VDJ segments to generate invariant/public cytomegalovirus-reactive CDR3 sequences (TRGV8-TRJP1-CATWDTTGWFKIF, TRDV2-TRDD3-CACDTGGY, and TRDV1-TRDD3-CALGELGD). Furthermore, both the generation of invariant TCRs and the intrathymic acquisition of effector functions were due to an intrinsic property of fetal hematopoietic stem and precursor cells (HSPCs) caused by high expression of the RNA-binding protein Lin28b. In conclusion, our data indicate that the human fetal thymus generates, in an HSPC/Lin28b-dependent manner, invariant γδ T cells with programmed effector functions.
Regulatory T Cells Expanded by Autologous Mature Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase Are Potent Suppressors of T Cell Proliferation.
Authors: Davi d J. Chung, Marco Rossi, Emanuela Romano, Jennifer Pressley, Christophe Antczak, David H. Munn, James W. Young
Journal: Blood (2008)
Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma
Authors: Philip Bucher, Tabea Erdmann, Paula Grondona, Wendan Xu, Anja Schmitt, Christoph Schürch, Myroslav Zapukhlyak, Caroline Schönfeld, Edgar Serfling, Daniela Kramer, Michael Grau, Pavel Klener, Claudia Lengerke, Klaus Schulze-Osthoff, Georg Lenz, Stephan Hailfinger
Journal: Blood (2019)
Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).
Authors: Daniel A. Pollyea, Andrew S. Artz, Wendy Stock, Sonali M. Smith, Christopher Daugherty, Lucy Godley, Todd Zimmerman, Olatoyosi M. Odenike, Michael Thirman, Elizabeth Rich, Richard Larson, Koen Van Besien
Journal: Blood (2004)
Prognostic Significance of Both the Cytoplasmic and Nuclear Overexpression of Yin-Yang 1 (YY1) among Patients with Multiple Myeloma (MM)
Authors: Sara Huerta-Yepez, Clara Rivera-Pazos, Massimo Libra, Stavroula Baritaki, Haiming Chen, James R. Berenson, Benjamin Bonavida
Journal: Blood (2008)
Allogeneic B Cell Response to H-Y Minor Histocompatibility Antigens after Donor Lymphocyte Infusion Correlates with Disease Response.
Authors: David B. Miklos, Katherine H. Miller, Haesook T. Kim, Stephanie J. Lee, Edwin P. Alyea, Corey Cutler, Joseph H. Antin, Robert J. Soiffer, Jerome Ritz
Journal: Blood (2004)
Clinical importance of circulating tumor cells in lung cancer patients.
Authors: Andrea Benedikova, Josef Srovnal, Jiri Klein, Pavel Skalicky, Marek Szkorupa, Karel Cwiertka, Lenka Radova, Marian Hajduch
Journal: Journal of Clinical Oncology (2013)

e22109 Background: Assessment of the circulating tumor cells (CTCs) in lung cancer patients could prevent burdensome surgery in understaged cases. Therefore we have tested the hypothesis that the presence of CTCs is a negative prognostic factor in these patients and correlates with poor survival. Methods: This was a prospective study to test the presence of CTCs in peripheral blood, pulmonary blood and bone marrow in 108 lung cancer patients (75 males, 33 females; mean age 66.2 years, ranging from 29 to 82 years) at the time of surgery using real-time RT-PCR for carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), lung-specific X protein (LUNX) and hepatocyte growth factor receptor (c-met). Results: We found a statistically significant association between c-met expression level in the pulmonary blood and clinical stage (p&lt;0.044) and lymph node involvement (p&lt;0.0023). C-met marker also showed significantly higher positivity ratio in the peripheral (p&lt;0.034) and pulmonary (p&lt;0.04) blood in patients with histologically proven lymphatic metastases than in patients with negative lymph nodes. The positivity of CTCs in peripheral blood or bone marrow using c-met was independent of clinical stage, age, sex and grading using Cox regression analysis (p=0.006, resp. 0.001). 82 patients followed up for more than 1 year were involved into the overall survival (OS) analysis. 27 of them (32.9 %) died, the OS median was 19.8 months. The patients with the presence of CTCs in the peripheral blood or the bone marrow using c-met had significantly shorter OS and higher hazard ratio (p&lt;0.024; HR=4.39 [95% CI: 1.58-12.22], resp. p&lt;0.008; HR=5.08 [95% CI: 1.79-14.43]). In addition, patients with the presence of CTCs detected in bone marrow using CEA and/or c-met had significantly shorter OS (p&lt;0.025; HR=3.08 [95% CI: 1.26-7.5]). Conclusions: Our study demonstrates that the presence of CTCs is independent negative prognostic factor in lung cancer patients. The analysis of CTCs is clinically feasible, reproducible and further studies focused on early clinical stages should demonstrate its applicability in individualization of adjuvant therapy in lung cancer patients and identification of individuals who would not benefit from extensive lung surgery.
Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Liver Cancer Among Postmenopausal Women
Authors: Jessica L. Petrick, Andrea A. Florio, Xuehong Zhang, Anne Zeleniuch‐Jacquotte, Jean Wactawski‐Wende, Stephen K. Van Den Eeden, Frank Z. Stanczyk, Tracey G. Simon, Rashmi Sinha, Howard D. Sesso, Catherine Schairer, Lynn Rosenberg, Thomas E. Rohan, Mark P. Purdue, Julie R. Palmer, Martha S. Linet, Linda M. Liao, I‐Min Lee, Jill Koshiol, Cari M. Kitahara, Victoria A. Kirsh, Jonathan N. Hofmann, Chantal Guillemette, Barry I. Graubard, Edward Giovannucci, J. Michael Gaziano, Susan M. Gapster, Neal D. Freedman, Lawrence S. Engel, Dawn Q. Chong, Yu Chen, Andrew T. Chan, Patrick Caron, Julie E. Buring, Gary Bradwin, Laura E. Beane Freeman, Peter T. Campbell, Katherine A. McGlynn
Journal: Hepatology (2019)

Background and Aims In almost all countries, incidence rates of liver cancer (LC) are 100%‐200% higher in males than in females. However, this difference is predominantly driven by hepatocellular carcinoma (HCC), which accounts for 75% of LC cases. Intrahepatic cholangiocarcinoma (ICC) accounts for 12% of cases and has rates only 30% higher in males. Hormones are hypothesized to underlie observed sex differences. We investigated whether prediagnostic circulating hormone and sex hormone binding globulin (SHBG) levels were associated with LC risk, overall and by histology, by leveraging resources from five prospective cohorts. Approach and Results Seven sex steroid hormones and SHBG were quantitated using gas chromatography/tandem mass spectrometry and competitive electrochemiluminescence immunoassay, respectively, from baseline serum/plasma samples of 191 postmenopausal female LC cases (HCC, n = 83; ICC, n = 56) and 426 controls, matched on sex, cohort, age, race/ethnicity, and blood collection date. Odds ratios (ORs) and 95% confidence intervals (CIs) for associations between a one‐unit increase in log 2 hormone value (approximate doubling of circulating concentration) and LC were calculated using multivariable‐adjusted conditional logistic regression. A doubling in the concentration of 4‐androstenedione (4‐dione) was associated with a 50% decreased LC risk (OR = 0.50; 95% CI = 0.30‐0.82), whereas SHBG was associated with a 31% increased risk (OR = 1.31; 95% CI = 1.05‐1.63). Examining histology, a doubling of estradiol was associated with a 40% increased risk of ICC (OR = 1.40; 95% CI = 1.05‐1.89), but not HCC (OR = 1.12; 95% CI = 0.81‐1.54). Conclusions This study provides evidence that higher levels of 4‐dione may be associated with lower, and SHBG with higher, LC risk in women. However, this study does not support the hypothesis that higher estrogen levels decrease LC risk. Indeed, estradiol may be associated with an increased ICC risk.
Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of <i>ERCC1</i>: SWOG S1201
Authors: Syma Iqbal, Shannon McDonough, Heinz-Josef Lenz, David Ilson, Barbara Burtness, Chaitali S. Nangia, Afsaneh Barzi, Charles J. Schneider, Jane Jijun Liu, Efrat Dotan, Katherine A. Guthrie, Howard S. Hochster
Journal: Journal of Clinical Oncology (2019)

PURPOSE Platinum-based therapy is the standard of care in patients who have HER2-negative, advanced esophagogastric cancer (AEGC). Retrospective data suggest that intratumoral ERCC1 levels may determine platinum sensitivity. A randomized, phase II study was performed in patients with AEGC to explore whether the efficacy of a platinum-based therapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) versus a non–platinum-containing regimen of irinotecan and docetaxel (IT) differed according to ERCC1 levels. PATIENTS AND METHODS Overall, 202 untreated patients with HER2-negative AEGC and a Zubrod performance status of 0-1 were evaluated prospectively for mRNA expression of ERCC1 level and then randomly assigned to FOLFOX or IT, stratified by the intratumoral statuses of ERCC1 low (&lt; 1.7) or high (≥ 1.7). Objectives were to assess progression-free survival (PFS) and overall survival (OS) in all patients treated with FOLFOX compared with IT, stratified by low and high ERCC1 levels, and to assess for interactive effects between ERCC1 expression and treatment arm. RESULTS Eighty-six percent of patients had ERCC1 values &lt; 1.7. Thus, evaluation of the ERCC1-high subgroup was limited. Grade ≥ 3 anemia, dehydration, diarrhea, and fatigue were greater in patients with IT. Occurrences of grade ≥ 3 neuropathy and decreased neutrophils were greater in patients with FOLFOX. In all patients, FOLFOX had a statistically superior median PFS compared with IT (5.7 v 2.9 months; hazard ratio, 0.68; P = .02). In patients with ERCC1 levels &lt; 1.7 receiving FOLFOX, PFS and response rate were statistically superior to IT, with no significant difference in OS. CONCLUSION The evaluation of ERCC1 in patients with upper GI tumors was thwarted by an overwhelming predominance of low ERCC1 mRNA expression. Nonetheless, distribution of treatment effects on PFS did not vary with expression. For all patients and for those with low ERCC1 expression, FOLFOX was superior in efficacy to IT.
Resistance to Apoptosis and Cell Proliferation in the hCG-PMl-RARα Transgenic Mouse Model Are Age-Related.
Authors: Priscila S. Scheucher, Barbara A.A. Santana, Rodrigo S. Abreu e Lima, Guilherme A.S. Santos, Aglair B. Garcia, Roberto P. Falcao, Pier Paolo Pandolfi, Eduardo M. Rego
Journal: Blood (2005)